necrosis factor (TNF) a and b (25-27), transforming The human immunodeficiency virus type 1 (HIV-1) engrowth factor b (28) and others according to the cell type codes an early regulatory protein called Tat (1, 2) . Tat (reviewed in Ref. 29) . In particular, TNF is increased in transactivates HIV-1 gene expression by interacting with HIV-1-infected individuals (30, 31) and is known to affect the Tat-activation response element (TAR) in the HIV long the vascular, immune, and central nervous systems, sugterminal repeat (LTR) (3) (4) (5) (6) (7) . Tat promotes transcriptional gesting a role for this cytokine in the pathogenesis of initiation of the integrated proviral genome and stimu-AIDS-KS, B cell lymphomas, and central nervous system lates the elongation of newly initiated viral transcripts (8-disorders (14, 25, 32-34) . In addition, TNF activates HIV-10). Tat has also been shown to be released by infected T 1 gene expression and rescues Tat-defective HIV-1 provicells (11) (12) (13) . In this extracellular form Tat activates HIV ruses (14, 35, 36) . TNF can also increase production of replication and rescues Tat-defective proviruses in a parinterleukin 1 (IL-1) and IL-6 (25), which are increased in acrine fashion (10) (11) (12) (14) (15) (16) (17) (18) . By a different mechanism HIV-1-infected individuals (37, 38) . Thus, activation of (receptor-mediated) extracellular Tat participates in the TNF by Tat may be part of a complex pathway in which development and progression of Kaposi's sarcoma (KS) HIV-1 uses viral products and host factors to increase (11, 12, 14, (19) (20) (21) (22) (23) . In addition, recent data indicate that its own expression, infectivity, and to induce disease (25).
Tat is involved in the T cell death occurring in AIDS by
Because of these effects of TNF, it is critical that any inducing or contributing to apoptosis (13, 24) . In HIV-1-gene therapy approach be able to block the Tat-induced infected or tat-transfected cells or when extracellular Tat gene expression of TNF in addition to inhibiting HIV repliis present at high concentrations, Tat can also activate cation. the expression of several cellular genes including tumor
The TAR element is present in all HIV RNA transcripts and forms a predicted stem-loop secondary structure that is required for Tat function (5, 6) . Expression of TAR results in the lack of activation of viral gene expression and diminished generation of progeny virus.
Recent data indicate that Tat-induced TNFb gene expression is mediated by a TAR-like element present in the TNFb 5 untranslated region although both SP1 and NFkB binding sites are also required for Tat activity (26). The TNFb messenger RNA leader region, in fact, contains a sequence which is 80% homologous to the bulge of the TAR and forms a predicted stem-loop structure that closely resembles the TAR of the HIV-LTR (TAR-like). This region is essential for TNFb transactivation by Tat (26). This apparent similarity of mechanisms suggested that the polymeric-TAR construct may inhibit Tat-mediated TNFb gene expression in addition to inhibition of HIV-1 gene expression.
To test this hypothesis, cotransfection experiments were performed with CD4
/ T cell lines such as Jurkat cells, H9 cells permanently transduced with the first exon of Tat (H9-Tat 1) and the 8E51 cell line which is chronically infected with a pol-defective HIV-1 provirus (26, 45). These cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37Њ in a humidified atmosphere containing 5% carbon dioxide in air. The plasmids used for the transfection experiments included pTNFbCAT and pCD7CAT which contain the chloramphenicol acetyltransferase (CAT) reporter gene ) were resuspended in 0.25 ml of growth medium containing 1 mM EGTA and mixed gently with in the absence of Tat (Fig. 1A and Table 1A ). Since LTR-50 TAR and LTR-0 TAR induced the same TNFbCAT activplasmid DNA. After 10 min incubation on ice, cells were electroporated at 960 m Far, 0.25 kV. After an additional ity in the absence of pCVTAT, this suggests that LTR-50 TAR alone does not suppress TNFb-CAT transcription. 10 min on ice, the cells were resuspended in 30 ml of growth medium and harvested 72 hr later. CAT assays Therefore, the difference in TNFbCAT activity observed with the LTR-50 TAR and the LTR-0 TAR in the presence were performed on cell lysate (normalized to total protein content) as described previously (46) . of pCVTAT is really dependent on the ability of LTR-50 TAR to trap the Tat protein and it is not due to the activaTo test whether the polymeric-TAR construct may inhibit Tat-mediated TNFb gene expression, 2 mg of tion of other inhibitory activities such as the effect of double-stranded kinase which has been reported to be pTNFbCAT and 2 mg of either pCVTAT or pCV0 were cotransfected with 6 mg of either LTR-0 TAR or LTR-50 activated by TAR (48).
To compare the level of transactivation or inhibition TAR into Jurkat cells. The amount of polymeric-TAR DNA transfected in these experiments is about a 2-fold and a of TNFb-mediated gene expression with the HIV-1 LTRmediated gene expression by Tat or polymeric-TAR, re-3-fold molar excess of pTNFbCAT and pCVTAT, respectively. As shown in Fig. 1A and Table 1A , pCVTAT inspectively, pCD7CAT (1 mg), pCV0 (3 mg), and either LTR-0 TAR or LTR-50 TAR (3 mg) were cotransfected in the creased pTNFbCAT activity by 4.7-fold, as compared to the control vector pCV0, and the polymeric-TAR decoys presence or absence of pCVTAT (0.1 mg) into Jurkat cells (Fig. 1B) . pCVTAT activated HIV-1 LTR-CAT (pCD7CAT) inhibited Tat-mediated TNFb gene expression by 4.4-fold (Table 1A) or 71% (Table 1B ) and up to 78% (Fig. 1A) as by 135-fold as compared to the control vector pCV0 and CAT activity.
the polymeric-TAR inhibited Tat-induced HIV-1 LTR-CAT of Tat and in a cell line chronically infected with a polactivity by 27.7-fold or 96% inhibition (Fig. 1B and Table  defective HIV-1 provirus (25). To determine whether poly-1A). Thus, polymeric-TAR decoy can inhibit both TNF and meric-TAR could inhibit TNFb activation in these sys-HIV-1 promoter activation induced by Tat. However, since tems, 5 mg of pTNFbCAT and 5 mg of either LTR-50 TAR these experiments were done by a transient transfection or its control LTR-0 TAR were transfected into these two system, only some of the cells will take up at the same cell lines. For 8E51 cells, pCD7CAT was used as a positime all the plasmids. This may reduce the efficacy of tive control to demonstrate the endogenous expression the polymeric-TAR construct which in permanently exof functional Tat protein. As shown in Fig. 2 and Table  pressing vector alone ( Fig. 3 and Table 1B ), indicating that polymeric-TAR specifically interferes with Tat function. it is Tat-inducible. When Tat activity is inhibited by the 21. Corallini, A., Altavilla, G., Pozzi, L., Bignozzi, F., Negrini, M., Rimessi, polymeric-TAR construct, the expression of TAR RNA will P., Gualandi, F., and Barbanti-Brodano, G., Cancer Res. 53, 1-7 (1993). also be decreased by the lower amount of Tat. Therefore, 22. Ensoli, B., Gendelman, R., Markham, P., Fiorelli, V., Colombini, S., no excess amount of TAR will be synthesized. This is an Raffeld, M., Cafaro, A., Chang, H.-K., Brady, J. N., and Gallo, obvious advantage for a gene therapy approach since it R. C., Nature 371, 674-680 (1994). may avoid problems of toxicity and unwanted effects due 23. Vogel, J., Hinrichs, S. H., Reynolds, R. K., Luciw, P. A., and Jay, G., to a constitutive expression. Since our previous studies for an effective therapy against AIDS.
